Adjunct Faculty, Biological Sciences Department
Education and Training
Ph.D., Rensselaer Polytechnic Institute, Troy, New York (1987-90)
Tel: (703) 582-1745; (703) 723-0034
Fax: (571) 223-1844
Mailing Address: Bawa Biotech LLC, 21005 Starflower Way, Ashburn, VA 20147
Dr. Raj Bawa is president of Bawa Biotech LLC, a biotech/pharma consultancy and patent law firm he founded in 2002. He is an inventor, entrepreneur and a registered patent agent licensed to practice before the U.S. Patent & Trademark Office. Trained as a biochemist and microbiologist, he has been an active researcher for the past two decades. He has extensive expertise in pharmaceutical sciences, biotechnology, nanomedicine, drug delivery, medical devices and biodefense-related scientific, FDA regulatory and patent law issues. He serves as scientific advisor to Teva Pharmaceutical Industries, Ltd., Israel. Since 1999, he has held various adjunct faculty appointments at Rensselaer Polytechnic Institute in Troy, NY where he currently is an adjunct professor. Since 2002, he has organized and chaired an annual international conference at Rensselaer that explores advances in nanosciences, pharma, biotech and related engineering fields. Since 2004, he has been an adjunct associate professor of natural and applied sciences at the Extended Learning Institute of NVCC in Annandale, VA. He recently served as principle investigator of two National Cancer Institute/SBIR contracts titled “Targeted nanocomplexed iron oxide for early detection with concurrent hyperthermia treatment of cancer” and “A targeted nanocomplex for early detection of lung cancer.”
Dr. Bawa has served as an advisor, consultant or expert to global corporations, U.S. government, law firms, universities, non-profits and NGOs. He previously served as patent legal advisor at Sequoia Pharmaceuticals, Gaithersburg, MD and as senior scientist at SynerGene Therapeutics, Inc., Potomac, MD. In the 1990s, Dr. Bawa held various positions at the US Patent and Trademark Office, including primary examiner (6 years) and instructor at the U.S. Patent Academy. He is a life member of Sigma Xi, founding director of the American Society for Nanomedicine, co-chair of the Nanotech Committee of the American Bar Association and Global Advisory Council Member of the World Future Society. He has authored over 100 publications, co-edited three texts, presented or chaired at over 200 conferences worldwide, and serves on the editorial boards of 16 peer-reviewed journals in biomedicine, law and business.
1. Bawa, R., G. Audette and I. Rubinstein. (Editors): Handbook of Clinical Nanomedicine – From Bench to Bedside, Pan Stanford Series in Nanomedicine, Volume 1, Pan Stanford Publishing, Singapore, 2014.
2. Szebeni, J. and R. Bawa. (Editors): Immune Effects of Biopharmaceuticals and Nanomedicines, Pan Stanford Series in Nanomedicine, Volume 2, Pan Stanford Publishing, Singapore, 2015. (in preparation)
3. Bawa, R., J. D. Bronzino and D. R. Peterson (Editors): Nanomedicine: Principles and Practices, CRC Press/Taylor Francis, Boca Raton, 2014.
4. Bawa, R., J. M. Nicholas and J. Conner. Copaxone® in the era of biosimilars and nanosimilars. In: Bawa, R., Audette, G. and Rubinstein, I. (Editors): Handbook of Clinical Nanomedicine – From Bench to Bedside, Pan Stanford Publishing, Singapore, 2014. (in press)
5. Bawa, R. Nanomedicine Section Editor, Biomedical Engineering Handbook, 4th edition, CRC Press/Taylor Francis, Boca Raton, 2014.
6. Bawa, R. (Editor): Nanotechnology – Law, Business and Commercialization, American Bar Association, Chicago, Illinois, 2015. (in preparation)
7. Mansour, H. M., C-W. Park and R. Bawa. (2014). Design and development of approved nanopharmaceutical products. In: Bawa, R., Audette, G. and Rubinstein, I. (Editors): Handbook of Clinical Nanomedicine – From Bench to Bedside, Pan Stanford Publishing, Singapore, 2014. (in press)
8. Bawa, R. (2013). FDA and nanotech: Baby steps lead to regulatory uncertainty. In: D. Bagchi, et al. (editors). Bionanotechnology: A revolution in biomedical sciences and human health. Wiley Blackwell, UK, pages 720-732.
9. Bawa, R. (2011). Regulating nanomedicine – Can the FDA handle it? Current Drug Delivery 8:227-234.
10. Bawa, R. (2010). The blood-brain barrier. In: D. H. Guston (editor). Encyclopedia of Nanoscience and Society, SAGE Publications, Inc., Thousand Oaks, CA, pages 54-55.
11. Kanwar, J. R., R. R. Mohan, R. K. Kanwar, K. Roy and R. Bawa. (2010). Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases. Nanomedicine 5(9):1435-1445.
12. Bawa, R. (2010). Nanopharmaceuticals. European Journal of Nanomedicine 3(1):34-39.
13. Bawa, R. (2009). Patenting inventions in bionanotechnology – A primer for scientists and lawyers. In: D. E. Reisner (editor). Bionanotechnology: Global Prospects, CRC Press, Boca Raton, FL 309-337.
14. Bawa, R. (2008). Nanoparticle-based therapeutics in humans: a survey. Nanotechnology Law & Business 5(2):135-155.
15. Bawa, R., S. Melethil, W. J. Simmons and D. Harris. (2008). Nanopharmaceuticals – patenting issues and FDA regulatory challenges. American Bar Association SciTech Lawyer 5(2):10-15.
16. Bawa, R. (2007). Special Report: Patents and nanomedicine. Nanomedicine 2(3):351-374.
17. Harris, D. and R. Bawa. (2007). The carbon nanotube patent landscape in nanomedicine: an expert opinion. Expert Opinion on Therapeutic Patents 17(9):1165-1174.
18. Bawa, R. (2007). Nanotechnology patent proliferation and the crisis at the US Patent Office. Albany Law Journal of Science and Technology 17(3):699-735.
19. Bawa, R. and S. Johnson. (2007). The ethical dimensions of nanomedicine. The Medical Clinics of North America 91(5):881–887.
20. O’Neill, S., K. Hermann, M. Klein, J. Landes and R. Bawa. (2007). Broad claiming in nanotechnology patents: Is litigation inevitable? Nanotechnology Law and Business 4(1):595-606.